"Klinick\u00E1 onkologie" . . "Berkovcov\u00E1, Jitka" . "Lung cancer is the leading cause of cancer deaths worldwide. Standard therapy of non-small cell lung cancer (NSCLC) includes platinum-based chemotherapy in combination with other anticancer drugs. Novel effective agents recently introduced into clinics are small molecule tyrosine kinase inhibitors of the epidermal growth factor receptor (Egfr1). Egfr1 is frequently constitutively activated in majority of human cancers. Up-regulation of the Egfr1 signaling is associated with overexpression of egfr1, which may be due to amplification of egfr1 gene in the tumors cells."@en . "Vorl\u00ED\u010Dek, Ji\u0159\u00ED" . "171-176" . "PREDIKCE \u00DA\u010CINNOSTI TYROZINKIN\u00C1ZOV\u00DDCH INHIBITOR\u016E EGFR1" . "Jano\u0161\u0165\u00E1kov\u00E1, Anna" . "443584" . "Dziechciarkov\u00E1, Marta" . . "[DBDC7FF546D1]" . "0862-495X" . "Kolek, Vit\u011Bzslav" . . . . . . . "PREDIKCE \u00DA\u010CINNOSTI TYROZINKIN\u00C1ZOV\u00DDCH INHIBITOR\u016E EGFR1" . "6"^^ . "Wiecek, Sylwia" . . . "Plicn\u00ED n\u00E1dory jsou celosv\u011Btovou nej\u010Dast\u011Bj\u0161\u00ED p\u0159\u00ED\u010Dinou \u00FAmrt\u00ED na malign\u00ED onemocn\u011Bn\u00ED. Standardn\u00ED terapie nemalobun\u011B\u010Dn\u00FDch plicn\u00EDch karcinom\u016F (NSCLC) vyu\u017E\u00EDv\u00E1 b\u011B\u017En\u00FDch platinov\u00FDch deriv\u00E1t\u016F v kombinaci s dal\u0161\u00EDmi cytostatiky. Nov\u00E9 mo\u017Enosti pacient\u016Fm nab\u00EDz\u00ED l\u00E9\u010Dba s pou\u017Eit\u00EDm n\u00EDzkomolekul\u00E1rn\u00EDch inhibitor\u016F hyperaktivovan\u00E9ho tyrozinkin\u00E1zov\u00E9ho receptoru pro epiderm\u00E1ln\u00ED r\u016Fstov\u00FD faktor (Egfr1)."@cs . . "6"^^ . "PREDICTION OF RESPONSE IN NON-SMALL CELL LUNG CANCERS"@en . . . "Egfr1; point mutations; tyrosine kinase; gefitinib; erlotinib; non-small cell lung cancer; k-ras"@en . "9"^^ . . . "P(1H-PK/45), Z(MSM6198959216)" . "3" . "PREDIKCE \u00DA\u010CINNOSTI TYROZINKIN\u00C1ZOV\u00DDCH INHIBITOR\u016E EGFR1"@cs . . "Gryg\u00E1rkov\u00E1, Ivona" . "PREDIKCE \u00DA\u010CINNOSTI TYROZINKIN\u00C1ZOV\u00DDCH INHIBITOR\u016E EGFR1"@cs . "Trojanec, Radek" . . . . . "Plicn\u00ED n\u00E1dory jsou celosv\u011Btovou nej\u010Dast\u011Bj\u0161\u00ED p\u0159\u00ED\u010Dinou \u00FAmrt\u00ED na malign\u00ED onemocn\u011Bn\u00ED. Standardn\u00ED terapie nemalobun\u011B\u010Dn\u00FDch plicn\u00EDch karcinom\u016F (NSCLC) vyu\u017E\u00EDv\u00E1 b\u011B\u017En\u00FDch platinov\u00FDch deriv\u00E1t\u016F v kombinaci s dal\u0161\u00EDmi cytostatiky. Nov\u00E9 mo\u017Enosti pacient\u016Fm nab\u00EDz\u00ED l\u00E9\u010Dba s pou\u017Eit\u00EDm n\u00EDzkomolekul\u00E1rn\u00EDch inhibitor\u016F hyperaktivovan\u00E9ho tyrozinkin\u00E1zov\u00E9ho receptoru pro epiderm\u00E1ln\u00ED r\u016Fstov\u00FD faktor (Egfr1)." . "19" . . . . . "CZ - \u010Cesk\u00E1 republika" . "RIV/61989592:15110/07:00002701!RIV07-MPO-15110___" . . "Hajd\u00FAch, Mari\u00E1n" . "RIV/61989592:15110/07:00002701" . "PREDICTION OF RESPONSE IN NON-SMALL CELL LUNG CANCERS"@en . . "15110" .